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Lysosomal protease cathepsin D is a prognostic marker in endometrial
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S_maary The present study investigates the prognostic value of immunohistochemically detected cathepsin D
expression in endometrial adenocarcinoma. Patients with surgically treated endometrial adenocarcinoma FIGO
stages I-III and consecutive irradiation therapy were included in the study. When we performed
immunohistochemistry to detect cathepsin D in 115 tissue specimens 35 cases showed a positive reaction. In
the univariate analysis cathepsin D expression showed significant prognostic value for overall survival (P-
value=0.007). In the multivariate analysis with established prognostic parameters (stage, grade) we found an
independent prognostic value for cathepsin D (P-value=0.002, relative risk=3.8, 95% confidence interval 1.4
- 10.0). Immunohistochemical detection ofcathepsin D could aid in predicting prognosis and planning therapy
for patients with endometrial adenocarcinoma.
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Cancer of the uterine corpus is the most common malignancy
of female pelvic genital organs. Increasing incidence of
carcinoma of the endometrium has been apparent in recent
years (Creasman, 1992). Generally accepted histological
parameters of prognostic value are histological grade, depth
of myometrial invasion, histological variant, lymphatic and
vascular invasion, pelvic and para-aortal nodal status and
clinical-surgical stage (Baltzer et al., 1983; Christopherson et
al., 1983; Hendricson et al., 1982; Ng and Reegan, 1970). The
influence of ovarian steroid hormones in the development of
abnormal proliferation ofthe endometrium is recognised. The
presence of steroid hormone receptors is of prognostic
importance, oestrogen and progesterone receptor status are
reported to be an independent prognostic factor for disease-
free survival (Clement and Scully, 1993). Progesterone
receptor-positive tumours appear to be more responsive to
therapy with progestin, whereas others may be more
responsive to chemotherapy (Creasman, 1993).
Cathepsin D is an oestrogen-dependent lysosomal protease
in breast tissues that facilitates tumour invasion by
promoting breakdown of connective tissue and basal
membrane (Rochefort et al., 1987). In the normal human
endometrium progesterone induces the accumulation of
cathepsin D. Cathepsin D levels are higher in normal human
endometrium during the luteal phase than in the follicular
phase and increase slightly during pregnancy (Maudelonde et
al., 1990). In endometrial adenocarcinoma cathepsin D levels
are higher than in normal endometrium during the follicular
phase, but there is no correlation to steroid hormone receptor
status (Maudelonde et al., 1990; Nazeer et al., 1994).
Cathepsin D is a well-known independent prognostic
factor in breast cancer, associated with metastasis and
overall survival (Spyratos et al., 1989; Tandon et al., 1990;
Thorpe et al., 1989). Limited information is available on the
prognostic value of cathepsin D regarding gynaecological
malignancies. We investigated the prognostic value of
cathepsin D in 115 cases of endometrial cancer by
immunohistochemistry.
Materials and methods
A total of 115 patients with surgically treated endometrial
adenocarcinoma FIGO stages I-III were included in the
study. Mean age was 64.3 (s.d. 9.6, minimum 36, maximum
85). Seven patients had a premenopausal hormonal status.
None of the post-menopausal women received hormonal
replacement therapy during the last 3 months before surgical
treatment. Diagnosis was established in all cases preopera-
tively by dilatation and curettage. All patients were treated
by total abdominal hysterectomy, bilateral salpingo-oophor-
ectomy between 1980 and 1989. In the seven premenopausal
patients surgical treatment was performed in four cases, two
at the follicular phase and two at the luteal phase of the
menstrual cycle. In the remaining three cases irregular
bleedings were the reason for unclear stage of the menstrual
cycle at the time of hysterectomy. Serous papillary
endometrial tumours were excluded. Lymph node staging
was not performed routinely during the whole observation
period and could therefore not be included in further
analysis. In cases of patients with stage I endometrial
adenocarcinoma the decision whether they received vaginal
contact radiation only or additional percutaneous pelvic
lymph node radiation depended on risk factors such as
tumour infiltration exceeding one-third of the myometrium,
high-grade tumour and vascular invasion. All patients in
advanced stages received both local and percutaneous
radiation treatment. For the after-loading method, iridium-
192 was used (2-3 x 7 Gy). Where post-surgical external
radiation was incorporated using cobalt-60, we tried to
achieve doses of 56 Gy at the pelvis. The endometrial biopsy,
uterus, ovaries and lymph node specimens were examined for
tumour type, grade and stage according to the International
Federation of Gynaecology and Obstetrics system (FIGO,
1990). All patients were followed up for at least 5 years and
some up to 13 years.
Immunohistochemistry
We performed immunohistochemistry using the primary
antibody to cathepsin D (Dako Polyclonal rabbit anti-
cathepsin D; code no. A561, Dako, Carpinteria, CA, USA).
The specificity of this antibody was determined in a Western
blot against purified cathepsin B, H, L and D. The antibody
showed no reaction with cathepsin B, H and L. The antibody
recognises the 52 kDa precursor (procathepsin D) and the
48 kDa intermediate, active form cathepsin D. The
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Fugwe 1 Granular intracellular staining of an endometrial
adenocarcinoma with antibodies against cathepsin D (Dako
Polyclonal rabbit anti-cathepsin D, haematoxylin counterstain-
ing; x 128).
intracellular staining of the antibody proves immunoreactiv-
ity of the precursor and the activated form of the enzyme in
the cytoplasm. The antibody stains macrophages, normal
fibroblasts, preferentially glandular epithelium such as sweat
ducts and glands in skin and myoepithelial cells of non-
lactating mammary glands. In breast cancer tumours this
antibody shows staining of variable intensity.
All sections tested are routine formalin-fixed paraffin-
embedded samples. Paraffin sections were soaked in xylene to
remove paraffin and rehydrated in graded alcohol series
(100-70%). To recover antigenicity we used the Antigen
Retrieval System (Bio Genex, San Ramon, CA, USA) twice
for 5 min in the microwave on high power (600 W), sections
were then washed in 10 mm phosphate-buffered saline (PBS)
(pH 7.6). The sections were incubated with cathepsin D
antiserum at 1:300 dilution for 60 min, then for a further
30 min with biotinylated anti-mouse and anti-rabbit link
antibody (Dako LSAB 2 Kit). After rinsing in PBS the
sections were coated wuLh streptavidin conjugated to alkaline
phosphatase for 10 min. The sections were rinsed in PBS,
incubated with fast red chromogen (naphthol phosphate
substrate in Tris buffer, fast red chromogen tablets 5 mg,
BioGenex) and then washed in distilled water. The sections
were finally counterstained with haematoxylin and mounted.
Control: the positive control slide was prepared from skin
tissue. In skin the antibody labels sweat ducts and glands.
The negative control slide was prepared from the same tissue
block as the specimen. Instead of using a primary antibody
we used a non-immune rabbit serum (Dako code no., X902,
69 mg ml ' diluted 1:600.
We used a semiquantitative method to determine
immunoreactivity. In endometrial tumours more than 10%
of strong and/or widespread intracellular cytoplasmic staining
was interpreted as positive (Figure 1). Weak and focal
staining less than 10% was regarded as a negative reaction.
Occasionally surrounding stromal tissue showed a positive
reaction. Macrophages and normal fibroblasts stained
strongly.
Statistical wnalisis
Results were analysed for the end point of overall survival.
We calculated survival probabilities by the product limit
method of Kaplan and Meier (Kaplan and Meier, 1958).
Univariate analysis was assessed using the log-rank test. For
multivariate analysis the generalised Cox models (Cox, 1972;
Schemper, 1992) were used to assess the independent effect of
cathepsin D expression. The potential prognostic factor was
added to a model of known prognostic factors: pathological
stage and histological grade. All P-values are results of one-
sided tests. When appropriate results were analysed by the
chi-square test the BMDP statistical software system (BMDP
Statistical Software, Los Angeles, CA, USA, 1990) was used.
Results
Ofthe 115 endometrioid adenocarcinomas studied, 80.7% (93
tumours) were typical endometrioid adenocarcinomas and
19.3% (22 tumours) endometrioid adenocarcinomas with
squamous differentiation according to the WHO/AFIP
classification of endometrial carcinoma (Silverberg and
Kurman, 1992). Endometrial adenocarcinoma pathological
stages I, II and III was present in 94, 12 and nine cases
respectively. Of the 94 stage I cases, 21 cases showed stage
IA, 46 IB, 27 IC. We found low-(Gl), moderate-(G2) and
Table I Correlation of cathepsin D expression in endometrial cancer with histological
myometrial invasion, and histological stage
type. differention.
Cathepsin D-
Total positive (%) P-value
Histological type
Typical endometrioid adenocarcinoma 93 34
Endometrioid adenocarcinoma with squamous 22 14 NS
differentiation
Histological stage
pTIlA 21 38
pTIB 46 26
pTIC 27 37 NS
pT2 12 8
pT3 9 44
Histological grade
GI 64 33
G2 28 29 NS
G3 23 26
Myometrial invasion
No myometrial invasion 22 41
Inner third 30 20 NS
Medium third 13 26
Deep third 40 35
NS, not significant.
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high-(G3) grade tumours in 55.7%, 23.3% and 20% of the
cases respectively. Thirty (26%) tumours invaded the inner
third, 23 (20%) the second third and 40 (35%) the outer third
of the myometrium. Twenty-two (19%) tumours were
confined to the endometrium.
We found no significant correlation of age and cathepsin
D expression. In cases with positive cathepsin D reaction
mean age was 65.1 (s.d. 8.67, minimum 49, maximum 85)
years and in the group with negative reaction mean age was
64.0 (s.d. 10.02, minimum 36, maximum 84) years.
Results of cathepsin D expression with histological type,
tumour grade, myometrial invasion and histological stage are
presented in Table I. Data from the univariate and
multivariate survival analysis are shown in Table I). The
number of premenopausal patients was too small to be
considered in statistical analysis. The survival distribution
function grouped by cathepsin D expression is shown in
Figure 2.
Disaio
Cathepsin D is a ubiquitous acidic protease. Three forms of
the enzyme are recognised: the 52 kDa precursor or
procathepsin D, the 48 kDa intermediate, and the 34 kDa
mature, stable form of the enzyme. In normal epithelium of
mammary glands negligible amounts of the two precursor
molecules accumulate intracellularly or are secreted (Nazeer
Table H Cathepsin D in endometrial cancer. Overall survival
analysis: univariate and multivariate analysis using the generalised
Cox models including pathological stage and histological grade
together with the candidate cathepsn D
Univanate Multivariate analysis
anaysis
P-vahle RR (95% CI)a P-value
Histological stage 0.06 2.5 (0.66-9.56) 0.05
Histological grade 0.10 1.4 (0.49-4.01) 0.27
Cathepsin D 0.007 3.8 (1.40-10.03) 0.01
expression
a RR (95% CI), estimated relative risk (95% confidence interval).
CD
>
0
Go
0 20 40 60 80 100 120
Time since initial treatment (months)
Figure 2 Kaplan- Meier survival analysis of patients with
cathepsin D-positive ( ) tissue expression compared with
patients with a negative (- ) result.
et al., 1992). In human breast cancer cell lines intracellular
procathepsin D processing is delayed and secretion is
markedly increased. Simultaneously the two precursor
molecules accumulate in the cells (Rochefort et al., 1989;
Nazeer et al., 1992). In breast cancer cells cathepsin D is
directly regulated at the mRNA level by oestrogen and
growth factors. It is also produced in oestrogen-responsive
endometrial cancer cell lines, but is not regulated by
oestrogen, although it is also responsive to growth factors
(Rochefort et al., 1989; Touitou et al., 1989). In the human
endometrium higher cytosolic levels of cathepsin D are
recognised during the luteal phase than in the follicular
phase of the menstrual cycle. This fact indicates that
cathepsin D is regulated in the endometrium by progester-
one, without any effect of oestrogen (Maudelonde et al.,
1990). In endometrial tissue cathepsin D is mainly
concentrated in the glandular epithelium. Although proges-
terone is absent in endometrial adenocarcinoma of post-
menopausal women, mean cytosolic concentration of
cathepsin D is significantly higher in comparison with
normal endometrium during the follicular phase. The
enhanced cathepsin D level may result from the higher
density of epithelial cells in endometrial adenocarcinoma
(Maudelonde et al., 1990; Nazeer et al., 1994).
In patients with endometrial carcinoma involvement of
pelvic or para-aortic lymph nodes is an important prognostic
factor (Lurain et al., 1991). A recent study proves the
correlation of cathepsin D and lymph node metastasis in
endometrial carcinoma (Nazeer et al., 1994). Cathepsin D
expression correlates with standard prognostic indicators of
endometrial carcinoma such as tumour differentiation and
myometrial invasiveness (Maudelonde et al., 1990; Nazeer et
al., 1992). Unfortunately, we could not establish a correlation
with the nodal status as surgical lymph node staging was not
performed on a regular basis.
There is a current discussion about the value of cathepsin
D as a prognostic marker (Cardiff, 1994). Some studies prove
high-level cathepsin D expression as an important factor for
overall survival in patients with node-negative breast cancer
(Tandon et al., 1990). Cathepsin D is also a well-known
prognostic factor for lymph node metastasis in breast cancer
(Spyratos et al., 1989). Other authors do not suppport the
prognostic value ofcathepsin D or demonstrate controversial
results (Henry et al., 1990; Castiglioni et al., 1994). Our study
is the first to show a prognostic value for cathepsin D in
endometrial cancer in a multivariate analysis.
Roger et al. (1994) have reported that the outcome of
immunohistochemical staining for cathepsin D correlates
with the cytosolic assay, being a valuable independent
variable that is useful in estimating prognosis. The difference
between cytosolic assays of whole tissue samples and the
immunohistochemical analyses can be due to the relative
contribution of the non-tumour cells. The biochemical
method includes the total cathepsin D content of all cells
and stroma, whereas the immunohistochemical method
measures tumour cell enzyme content alone (Rochefort,
1992; Castiglioni et al., 1994; Roger et al., 1994). In this
sense immunohistochemical detection is more specific for the
tumour tissue. On the other hand immunohistochemical
preparation techniques and reagents are not standardised
between the different studies and different antibodies have
been used in former investigations (Cardiff, 1994). Standar-
dised immunohistochemical techniques on well-defined
antibodies are important in providing reliable prognostic
interpretations of cathepsin D in tumours (Cardiff, 1994). In
our study we used the same antibody and immunohisto-
chemical preparation technique as described in a recent
comparative immunohistochemical and cytosolic assay study
on endometrial cancer (Nazeer et al., 1994). They suggested
immunohistochemically detected cathepsin D as a possible
predictive factor. In our study immunohistochemically
detected cathepsin D expression in endometrial adenocarci-
noma showed a significant prognostic value for overall
survival. Patients with tumours expressing cathepsin D hadCathepsin D i endomeIl cancer
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a significantly- worse survival probability (Figure 2). In the
multivariate analysis the association of cathepsin D with an
unfavourable prognosis stayed significant.
If the association With the probability of lymph node
metastasis could be established in further studies then
cathepsin D could aid in decision making. especially in
cases Without initial surgical staging. As we found a
significantly worse prognosis in endometrial cancer in cases
with cathepsin D expression immunohistochemical detection
of cathepsin D in a reliable standardised method could aid in
predicting prognosis and planning therapy for patients With
endometnral adenocarcinoma.
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